Status:
COMPLETED
Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia
Lead Sponsor:
Fondation Hôpital Saint-Joseph
Collaborating Sponsors:
Versailles Hospital
Centre Hospitalier Victor Dupouy
Conditions:
Coronavirus
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
The research is a prospective, multicentric (Groupe hospitalier Paris Saint-Joseph, Centre Hospitalier de Versailles André Mignot and Centre Hospitalier Victor Dupouy), non-interventional, prospective...
Detailed Description
The reason for the involvement of overweight in the severity of viral respiratory pathologies, particularly during influenza and coronavirus infections, has been the subject of numerous studies which ...
Eligibility Criteria
Inclusion
- Patient aged over 18 years
- French-speaking
- Patient whose Covid-19 respiratory infection was confirmed by laboratory tests, PCR and any other commercial or public health tests
- Patient hospitalized in intensive care unit and under invasive mechanical ventilation for less than three days (early inflammatory phase)
- Adult acute respiratory distress syndrome according to the Berlin definition
- Patient on long-term statin therapy regardless of the rationale for treatment (or without treatment for the control group).
Exclusion
- Patient/family or "medical" proxy who refuses the patient's participation in the study
- Patient under guardianship or curatorship
- Patient deprived of liberty
- Patient under the safeguard of justice.
Key Trial Info
Start Date :
April 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 6 2022
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT04485364
Start Date
April 14 2020
End Date
June 6 2022
Last Update
March 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupe Hospitalier Paris Saint-Joseph
Paris, France, 75014